Notably, addition of anti-PD-1 therapy to RMC-4550 or/and RMC-4998 extended the survival of mice with orthotopic KPARG12C tumours and resulted in CRs in those groups treated with the RAS(ON) G12C-selective inhibitor (Fig. 3d), even though the period of treatment was only 2 weeks. This evidence concerns the gene PDCD1 and neoplasm.